A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)
A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)
Recruiting · NCT05190471 · Registry updated 2025-03-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML) | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 1 | 2025-03-10 | NCT05190471 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Bio-Path Holdings, Inc. | 4 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| MD Anderson Cancer Center | Houston | United States | 589 |
| Scripps Green Hospital | La Jolla | United States | 14 |
| UCLA Medical Center | Los Angeles | United States | 4 |
| Weill Cornell Medical College - NewYork-Presbyterian Hospital | New York | United States | 2 |